YNIOS Pharma 3A
- Eligible for a tax reduction
.jpg?locale=en)
Jean F Plucker
Co-founder
Throughout his career, Jean François has specialized in technology transfers between university or federal laboratories and private industrial companies. His strength lies in combining scientific and economic logic. At YNIOS Pharma, he brings extensive experience in management, international trade, and intellectual property.
Philippe Van Wesepoel
Co-founder
Co-Founder & CSO
With a scientific background and an MBA, Philippe has experience in various therapeutic areas of the pharmaceutical industry, demonstrating both practical sense and scientific rigor. His curiosity and determination allow him to thoroughly explore issues, focusing on improving quality of life. The values and mission of YNIOS PHARMA align well with his own: developing more effective and better-tolerated therapeutic solutions through a new concept that constitutes a disruptive innovation.
TAX SHELTER 45%
Investments in this company benefit from a 45% personal income tax reduction. Read more…
Fact sheet
| Advised by a professional start-up advisor | |
| Valuation is set by the co-investor or incubator | |
| Co-investor or incubator will be members or observers to the board | |
| At the closing, an incubator, accelerator, or studio will have shares | |
| At the closing, the entrepreneurs have contributed a minimum of €15,000 in cash in exchange for shares | |
| Raised €10,000 during a private phase | |
| At the closing, a professional co-investor will have invested at least €25,000 | |
| Prior fundraising in equity or convertible loan with 10 or more investors | |
| Seasoned entrepreneurs | |
| Minimum 2 active entrepreneurs | |
| Valuation set by an organisation specialized in valuations of comparable size | |
| Valuation is less than €1 million or 10x last year’s turnover |
Raise summary
| Crowd investments | €56,000 |
| Committed by others | €0 |
| Amount raised | €56,000 |
| Minimum round | €25,000 |
| Maximum round | €300,000 |
| Shares in the company (total round) | 4.773% |
| Pre-money valuation | €5,985,300 |
| Post-money valuation min. | €6,010,300 |
| Post-money valuation max. | €6,285,300 |